Changes to a Borrowing Agreement with Financial Covenants
D.Western Therapeutics Institute, Inc. (the Company)
Neurogenic pain treatment DW-5LBT and cell product for regenerative medicine DWR-2206
A discrepancy arose for these development-stage products between the development plans established when the loans were initially borrowed and the outlook for the launch timing.
Fiscal year ending December 2026 (impact on the Company's consolidated results)
The Company expects the impact on its consolidated results for the fiscal year ending December 2026 to be minor.
The Company will maintain positive net assets on its unconsolidated and consolidated balance sheets as of the end of each fiscal year, and will maintain fixed-term deposits at or above the aggregate outstanding balance of borrowings from the lenders. The repayment due dates are 30 September 2029 and 30 June 2030.
| Item | Details |
|---|---|
| Event name | Changes to a Borrowing Agreement with Financial Covenants |
| Date of occurrence | 30 June 2026 (date the amendment agreements were executed) |
| Subject Entity | D.Western Therapeutics Institute, Inc. (the Company) |
| Target Locations / Products | Neurogenic pain treatment DW-5LBT and cell product for regenerative medicine DWR-2206 |
| Cause | A discrepancy arose for these development-stage products between the development plans established when the loans were initially borrowed and the outlook for the launch timing. |
| Accounting period in which recognized | Fiscal year ending December 2026 (impact on the Company's consolidated results) |
| Impact on Earnings Forecast | The Company expects the impact on its consolidated results for the fiscal year ending December 2026 to be minor. |
| Outlook | The Company will maintain positive net assets on its unconsolidated and consolidated balance sheets as of the end of each fiscal year, and will maintain fixed-term deposits at or above the aggregate outstanding balance of borrowings from the lenders. The repayment due dates are 30 September 2029 and 30 June 2030. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A discrepancy arose between the development plans established when the loans were initially borrowed and the outlook for the launch timing of the neurogenic pain treatment DW-5LBT and the cell product for regenerative medicine DWR-2206.